Adcytherix: Revolutionizing Cancer Treatment with Innovative ADC Technology

Adcytherix Secures €105 Million in Series A Funding to Advance Novel Antibody Drug Conjugates

Marseille-based Adcytherix, a biopharmaceutical company specializing in the development of innovative antibody drug conjugates (ADC), has successfully raised €105 million in a Series A financing round. The primary objective of this funding is to advance the company’s lead candidate and address the unmet medical needs of patients suffering from various diseases.

The financing round was co-led by prominent investors including Andera Partners, Angelini Ventures, Bpifrance (through both Large Venture and InnoBio investment strategies), and Kurma Partners. Additionally, Surveyor Capital, aMoon, and existing shareholders such as Pontifax, DawnBiopharma, Pureos Bioventures, and RA Capital also participated in the funding. This marks the first investment from Andera Partners’ new BioDiscovery 7 fund.

Jack Elands, the Chief Executive Officer and Founder of Adcytherix, expressed his enthusiasm about the successful completion of the funding round. He stated, “Closing the largest ADC-focused Series A in Europe in 2025 validates our science, our vision, and the exceptional work of our team since inception just 18 months ago. We are proud to have attracted a world-class syndicate of investors who share our ambition to develop breakthrough ADCs for patients resistant to the current classes of ADCs.”

The Series A financing of Adcytherix follows other significant investments in the bioconjugate and oncology sectors, such as Tubulis’s recent €308 million Series C round and Ciloa’s €6.5 million raise. These developments highlight the growing investor interest in novel biologic modalities in Europe, particularly in the field of targeted oncology drug development.

Sofia Ioannidou, PhD, Partner at Andera Partners, commended Adcytherix for its deep ADC expertise and differentiated lead program. She emphasized the company’s distinctive strategy focused on novel payload classes that have the potential to expand the reach of ADCs to tumors that currently do not respond well to this treatment modality.

Founded in 2024, Adcytherix aims to become a significant player in the field of ADC technology for targeted cancer therapy. The new funding will support the advancement of its lead candidate ADCX-020 into clinical trials, with plans to file investigational new drug applications by the end of 2025.

In addition to advancing its lead candidate, Adcytherix plans to expand its pipeline of proprietary ADCs using novel payloads. Sofia Ioannidou of Andera Partners will also join the Supervisory Committee following the successful Series A financing.